We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
SYNACT.ST

Price
17.94
Stock movement down
-0.06 (-0.33%)
Company name
SynAct Pharma AB
Exchange
(ST
,
Currency
SEK
)
Sector
Healthcare >
Biotechnology
Market cap
740.86M
Ent value
750.34M
Price/Sales
-
Price/Book
4.38
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
33.07%
1 year return
115.37%
3 year return
-34.45%
5 year return
13.46%
10 year return
-
Last updated: 2025-04-04

DIVIDENDS

SYNACT.ST does not pay dividends or no data was received

VALUATION

Valuation Ratios

Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Valuation (Sales/Book Value) data
Price to Sales-
Price to Book4.38
EV to Sales-

FINANCIALS

Per share

Per share data
Current share count41.30M
EPS (TTM)-3.74
FCF per share (TTM)-2.22

Income statement

Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-85.46M
Net income (TTM)-154.57M
EPS (TTM)-3.74
EPS (1y forward)-

Margins

Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Please create a free account or log in to access this chart
Balance Sheet data
Cash38.49M
Net receivables17.50M
Total current assets63.53M
Goodwill0.00
Intangible assets152.02M
Property, plant and equipment0.00
Total assets217.13M
Accounts payable6.45M
Short/Current long term debt1.43M
Total current liabilities16.36M
Total liabilities47.97M
Shareholder's equity169.16M
Net tangible assets0.00

Cash flow

Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-91.81M
Capital expenditures (TTM)0.00
Free cash flow (TTM)-91.81M
Dividends paid (TTM)0.00

Financial returns

Please create a free account or log in to access this chart
Financial returns data
Return on Equity-91.37%
Return on Assets-71.19%
Return on Invested Capital-91.10%
Cash Return on Invested Capital-54.12%

STOCK INFORMATION

Stock chart

Stock price data
Open17.75
Daily high18.18
Daily low17.17
Daily Volume215K
All-time high143.40
1y analyst estimate15.00
Beta0.65
EPS (TTM)-3.74
Dividend per share-
Ex-div date-
Next earnings date30 May 2025

Downside potential

Downside potential data
SYNACT.STS&P500
Current price drop from All-time high-87.49%-12.44%
Highest price drop-96.33%-56.47%
Date of highest drop1 Nov 20239 Mar 2009
Avg drop from high-40.63%-11.07%
Avg time to new high23 days12 days
Max time to new high823 days1805 days
COMPANY DETAILS
SYNACT.ST (SynAct Pharma AB) company logo
Marketcap
740.86M
Marketcap category
Small-cap
Description
SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases. SynAct Pharma AB was founded in 2012 and is headquartered in Lund, Sweden.
Employees
5
Website
https://synactpharma.com
Investor relations
-
SEC filings
SYNACT.ST SEC filings
CEO
Country
Sweden
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
UNDERSTAND THE BUSINESS
COMPANY NEWS
All newsPress releases
No items found
Disclaimer
Skyfall Technology OÜ assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness. Please also note, that any action you take upon the information provided on this website is strictly at your own risk. This website is intended to be used and must be used for informational purposes only and you should take independent financial advice from a professional and independently research and verify everything you see on the site.
Menu
HomePortfolio ManagementCompany ScreenerGreen InvestmentExchangesContact Us
Language
ENHUNOSVDAFIESDENLFRITPTPLCSSKROELTRRUAF
© 2024 Skyfall Technology OÜ All Rights Reserved